ACA. V. Chaika

A. V. Chaika

*This is an algorithmically generated author record based on publicly available information.

A. V. Chaika has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Heterogeneity of immunohistochemical status of microsatellite instability in gastric cancer: clinical-pathological associations and prognostic significance

    by E.E. Dresvyankina, A.V. Chaika, V.M. Khomyakov, N.A. Oleynikova, N.V. Danilova

    Objective. The investigation of the prevalence of heterogeneity in immunohistochemical staining of mismatch repair system markers (MMR heterogeneity) in gastric cancer (GC), search for correlations with clinical and morphological parameters, and analysis of the prognostic role of this phenomenon. Material and methods. Histological specimens stained immunohistochemically with antibodies to MMR markers (MSH2, MSH6, MLH1, PMS2; full-size surgical material from patients with GC, n=310) were analyzed. Two heterogeneous phenotypes were identified: 1) MMR-positive/heterogeneous — some tumor cells lose nuclear staining, while staining is preserved in other tumor cells and in the stroma, 2) MMR-negative/heterogeneous — in cases of MMR-negative tumors showing heterogeneous staining of preserved MMR markers. Statistical analysis was performed using IBM SPSS 26 software. Results. MMR-positive/heterogeneous tumors accounted for 11% of cases (n=34), MMR-negative/heterogeneous tumors — 2.3% (n=7). In MMR-positive/heterogeneous tumors, compared with MMR-positive tumors, there was a higher frequency of absence of signet ring cells (p<0.001), 1—2 macroscopic forms (p=0.046), papillary and tubular histological subtypes (p<0.001), intestinal histological subtype according to P. Lauren (p<0.001), higher differentiation grade (p<0.001), and earlier stage of disease (p=0.024). MMR-positive/heterogeneous status was associated with the tendency to longer overall survival (p=0.050; median 61 months vs. MMR-positive — 36 months). MMR-negative/heterogeneous and MMR-negative tumors did not differ statistically in terms of the parameters studied. Conclusion. MMR-heterogeneous tumors in GC, distinguished from MMR-positive, are characterized by a more favorable clinical and morphological profile and the tendency to longer survival compared to the latter. However, it is important to note the small number of cases in the MMR-negative/heterogeneous tumor group, as well as the heterogeneity of the clinical and morphological parameters among patients in the subgroups identified based on MMR status. This necessitates confirmation of the observed trends in survival differences in larger patient cohorts. Consequently, it is necessary to classify heterogeneous cases into separate subgroups, followed by a detailed study of their pathogenetic, predictive, and prognostic characteristics.

  • Possibilities of laparoscopic surgery in the treatment of patients with retroperitoneal tumors

    by A.B. Ryabov, V.M. Khomyakov, D.D. Sobolev, I.V. Kolobaev, N.V. Vorobyev, N.M. Abdulkhakimov, A.V. Chaika, K.I. Salimzyanov, A.A. Krasheninnikov, A.B. Utkina, et al.

    Today, radical surgical intervention is still one of the main methods of treatment for the majority of non-organ tumors in the retroperitoneal space. The rapid development of minimally invasive surgery in the last 10 years has been accompanied by an increase in the number of publications devoted to laparoscopic surgery of retroperitoneal formations. Minimally invasive surgery is a safe and technically feasible alternative to traumatic laparotomy access for localized tumors. The article presents a series of clinical observations and a review of the literature on this problem. Further accumulation of experience in performing this type of surgery and follow-up of these patients will make it possible to evaluate the long-term results and form criteria for selecting patients for minimally invasive treatment.

  • Another sight at Gastric Cancer Molecular Classification: novel subtypes based on expression of CDX-2, E-cadherin, Epstein-Barr virus RNAs, MMR proteins

    by N.V. Danilova, Yu.YU. Andreeva, V.M. Khomyakov, A.V. Chaika, D.V. Kalinin, E.E. Porubayeva, P.G. Malkov

    Objective. This study explores the immunohistochemical and prognostic characteristics of gastric cancer (GC). Material and methods. The research analyzed surgical samples from 310 GC patients who had not received chemotherapy or radiotherapy prior to surgery. Each sample was immunohistochemically stained for 23 markers (MSH2, MSH6, MLH1, PMS2, MUC2, CDX2, MUC5AC, CD10, E-cadherin, β-catenin, Claudin-1, Claudin-3, Claudin-4, CD44, p53, PD-L1 (SP142), PD-L1 (SP236), HER2, CD4, CD8, CD68, CD1a, LMP-1), and in situ hybridization for Epstein-Barr virus RNA (EBER) was also conducted. Results. The analysis led to the development of a molecular classification of gastric cancer, comprising five molecular subtypes: MMR-deficient, EBER-positive, E-cadherin aberrant, CDX2-positive, and CDX2-negative. The CDX2-positive subtype occurs in 49.7% of GC cases; it includes papillary and mucinous GC with less depth of invasion, no lymph node involvement, and lower clinical stage and has a relatively favorable prognosis (median survival 47 months). The CDX2-negative subtype occurs in 16.1% of GC cases; it includes tumors of diffuse and intermediate type by P. Lauren, primarily located distally in the stomach, with a greater depth of invasion and a higher clinical stage. The CDX2-negative subtype is characterized by positive expression of MUC5AC and unfavorable prognosis (median survival 23 months). Conclusion. A new five-tier molecular classification of gastric cancer has been developed. Two of the five subtypes have been identified and characterized for the first time. The identified subtypes have promising implications for the targeted therapy of gastric malignancies.


  • Open Access

    Treatment outcomes in young adults with gastric cancer

    by D. M. Pugaev, A. B. Ryabov, V. M. Khomyakov, I. V. Kolobaev, A. K. Kostrygin, O. A. Aleksandrov, G. S. Pogosуan, D. D. Sobolev, A. V. Chayka, A. B. Utkina, et al.

    Introduction. According to global data, gastric cancer (GC) is the 5-th most common malignancy with a high cancer-related mortality rate. However, in recent decades, there has been a tendency towards an increase in the incidence of GC among young patients (18 to 40 years old), which currently amounts to 4.4–9.8%. Aim: to evaluate the effectiveness of surgical, combined and palliative treatment options in early-onset GC. Material and Methods. the study included 129 patients aged 18–45 years, who underwent radical, cytoreductive and palliative surgery with or without combination with drug therapy for localized, locally-advanced and primary disseminated GC. the patients were divided into three clinical groups: 1) the surgical group (n=27) included patients with only surgical treatment; 2) the group of combined treatment (n= 58) included patients with PCI 7 who underwent systemic CT in combination with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Results. the median overall survival (OS) in three groups was 58, 30 and 13 months, respectively. In patients with IV stage of disease who underwent HIPEC with CC0 surgery, OS in the 2nd group was 17 in comparison with 13 months in the third group (PIPEC). Conclusion. Aggressive multimodal treatment in the absence of comorbid status in young patients will allow for intensification of both the perioperative drug therapy component and the implementation of extended multivisceral resections that facilitate radical surgical treatment to improve both DFS and OS.

  • Laparoscopic repair of hiatal hernia after minimally invasive esophagectomy

    by A.B. Ryabov, V.M. Khomyakov, N.M. Abdulkhakimov, A.V. Chaika

    Postoperative hiatal hernia is a rare and specific complication after esophagectomy. This complication leads to emergency and affects mortality. Incidence of this complication has increased due to the great number of minimally invasive procedures over the past decades. In addition, chronic cough, preoperative hiatal hernia and transhiatal approach also increase the risk of recurrent hernias. Most post-esophagectomy hiatal hernias do not require emergency surgery. About 70% of patients have symptoms reducing the quality of life. About 25% of cases are asymptomatic and discovered incidentally during follow-up examinations. The role of surgery for asymptomatic post-esophagectomy hernias is a matter of debate because the risk of symptoms or complications is poorly predictable. Surgical treatment is the only radical method for symptomatic or complicated hernias. However, there is still no consensus regarding surgical approach and technique. Most surgeons prefer open surgery fearing severe adhesive process and other technical difficulties. Laparoscopic approach is widely accepted as the “gold standard” for primary hiatal hernia. However, minimally invasive access for post-esophagectomy hiatal hernias is not sufficiently studied and described in several case reports. Currently, it is very important to study the risk factors of hiatal hernias after esophagectomy. We present successful laparoscopic repair of hiatal hernia after hybrid McKeown esophagectomy.


  • Open Access

    Nephronsparing surgery for retroperitoneal sarcomas

    by A. B. Ryabov, A. V. Chaika, V. M. Khomyakov, О. А. Александров, A. K. Kostrygin, D. D. Sobolev, G. S. Pogosyan, S. V. Arzumanov, N. V. Vorobyov, V. V. Cheremisov, et al.

    Objective: to clarify the indications for the use of nephron-sparing technologies in surgical treatment of patients with retroperitoneal sarcomas. Material and Methods. The study included 64 patients with primary retroperitoneal sarcomas with kidney and renal pedicle invasion, who underwent surgical treatment in the Thoracic-abdominal Department of the P.A. Herzen Moscow Oncology Research Institute from 2010 to 2021. Twenty-one patients underwent nephrectomies, and 43 patients underwent nephron-sparing surgery. The morphological profile of sarcomas, age and gender of the patients, feasibility of using nephron-sparing technologies, postoperative complications, and long-term outcomes in patients of both groups were analyzed. Results. Forty-three patients with primary retroperitoneal sarcomas with invasion of the renal parenchyma, ureter, and renal pedicle underwent nephron-sparing surgery (precision mobilization of the kidney, ureter and vascular structures of the kidney from tumor tissue, kidney resection, ureteral stenting, resection of the renal vein orifices, resection of the ureters, and kidney autotransplantation). Postoperative complications were observed in 19.0 % of nephrectomy group patients (4 pts: II, IIIB, IV and V types according to Clavien–Dindo) and in 30.2 % of nephron-sparing group patients (15 pts: types II – 8, IIIA – 1, IIIB – 3, IV – 1). No statistical differences in the relapse-free period and survival time between two groups were observed. The 1-, 3- and 5-year survival rates were 84.1 %, 65.9 %, and 51.4 %, respectively. Multifactorial analysis showed that mortality increased significantly in patients over 64 years of age and was associated with both disease recurrence and concomitant pathology (p=0.009). There was also a trend toward decreased survival in patients with leiomyosarcoma (p=0.066). Conclusion. In retroperitoneal sarcomas, tumor resection with preservation of organs and structures not directly invaded by the tumor is the optimal surgical strategy. Nephron-sparing technologies do not worsen both immediate and long-term treatment outcomes. For leiomyosarcoma, tumor resection with nephrectomy is the most suitable approach.

  • Pressurized intraperitoneal aerosol chemotherapy in combination with cytoreductive surgery in patients with gastric cancer and limited peritoneal carcinomatosis

    by S.A. Aksenov, V.M. Khomyakov, A.B. Ryabov, I.V. Kolobaev, D.D. Sobolev, O.S. Kuznetsova, A.B. Utkina, N.M. Abdulkhakimov, K.I. Salimzyanov, A.V. Chayka, et al.

    Cytoreductive surgery in combination with preoperative chemotherapy (also known as conversion surgery) is a promising treatment option for patients with limited peritoneal carcinomatosis. Local chemotherapy combined with cytoreductive procedures is widely discussed in literature as preventive approach for intraoperative dissemination. Objective. To This study aimed to evaluate the safety and efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in combination with cytoreductive surgery for patients with gastric cancer and limited peritoneal carcinomatosis (PCI < 7). Material and methods. Between 2019 and 2023, in total 20 patients with gastric cancer and limited peritoneal carcinomatosis underwent cytoreductive surgeries combined with PIPAC session at the NMIC of Radiology, Ministry of Health, Russian Federation. Results. Of the 21 patients, 3 (31.1%) had a partial response, in 17 patients primary tumor stabilization was observed after preoperative treatment, in 10 patients (50%), a complete response of peritoneal metastasis was achieved. All patients underwent complete cytoreduction (R0/CC-0). Major pathological response of the primary tumor was achived in 2 (10%) patients — TRG1a per Becker and in 4 (20%) — TRG1b per Becker, TRG2 and TRG3 in 5 (25%) and 9 (45%) patients, respectively. The median overall survival was 27 months and the disease-free survival was 7 months. 1-year and 2-year overall survival rates were 95% and 60%, respectively. Conclusion. Cytoreductive surgery in combination with PIPAC is feasible and safe. The survival rates demonstrate the potential effectiveness of this method. However, in order to make a clear assessment of the efficacy of adjuvant intraperitoneal chemotherapy as an approach for preventing intraoperative dissemination during cytoreductions, further randomized controlled trials is needed.


  • Conversion surgery for gastric cancer with limited peritoneal carcinomatosis

    by S.A. Aksenov, V.M. Khomyakov, A.B. Ryabov, I.V. Kolobaev, D.D. Sobolev, A.B. Utkina, K.I. Salimzyanov, A.K. Kostrygin, A.V. Chayka, A.D. Kaprin

    Conversion surgery for disseminated gastric cancer is attracting increasing attention as a new therapeutic strategy. A number of European and Asian studies on this topic have presented data on the advantage of performing cytoreductive surgery in a limited group of patients. Objective. To evaluate the safety and efficacy of conversion surgery for gastric cancer with limited peritoneal carcinomatosis. Material and methods. In the period from 2015 to 2022, 45 cytoreductive surgical interventions in patients with limited peritoneal carcinomatosis (PCI ≤7) in gastric cancer were performed in National Medical Radiology Research Center. Results. After preoperative drug treatment, 24 cases showed complete regression of carcinomatosis foci confirmed histologically and cytologically, while the remaining cases achieved partial response or stabilization. Surgical intervention was supplemented with hyperthermic intraoperative intra-abdominal chemotherapy or sessions of intra-abdominal aerosol chemotherapy. The extent of cytoreduction was considered as R0/CC-0 in 38 (84%) of 45 patients. Median overall survival was 24.1 months, with overall one- and two-year survival rates of 84.4 and 52%, respectively. Conclusion. Analysis of the results of conversion surgery for gastric cancer with limited peritoneal carcinomatosis has demonstrated the safety and efficacy of this approach with careful selection of patients. Further recruitment and analysis of the accumulated experience will make it possible to clarify the criteria for selecting patients for conversion surgery, as well as the optimal regimens of perioperative drug treatment.

  • Prognostic significance of PD-L1 expression as a potential predictor of survival in gastric cancer

    by T.N. Sotnikova, N.V. Danilova, T.V. Polushkina, P.G. Malkov, A.V. Chayka, V.M. Khomyakov, D.V. Kalinin

    В настоящее время активно изучается влияние экспрессии PD-L1 у пациентов с опухолями различных локализаций, однако данные остаются неоднозначными. Исследования об экспрессии PD-L1, выявленной клонами SP142 и SP263 при раке желудка (для препаратов атезолизумаб и дурвалумаб соответственно), в литературе единичны. Также не установлена прогностическая роль экспрессии PD-L1 у пациентов, не получавших терапию ингибиторами контрольных точек иммунитета. ЦЕЛЬ ИССЛЕДОВАНИЯ Определить уровень экспрессии PD-L1 (клоны SP263 и SP142, Roche Ventana) в образцах рака желудка и оценить его влияние на общую выживаемость у пациентов, не получавших адъювантную терапию ингибиторами контрольных точек иммунитета. МАТЕРИАЛ И МЕТОДЫ В исследование был включен 131 пациент с верифицированным диагнозом рак желудка. Антителами к PD-L1 SP263 был окрашен материал, полученный у 127 больных, антителами к PD-L1 SP142 — у 126. Для оценки предикторов выживаемости использовалась многофакторная регрессионная модель Кокса с алгоритмом пошагового исключения Вальда. РЕЗУЛЬТАТЫ Общая 5-летняя выживаемость больных в группе PD-L1-негативных опухолей была значительно ниже таковой в группе PD-L1-позитивных опухолей, которая составила 50 и 40% также для обоих клонов (p=0,027). Увеличение экспрессии PD-L1 клона SP263, определенное как методом CPS, так и методом TPS, уменьшает вероятность летального исхода в 1,35 раза (p=0,02) и в 1,61 раза (p=0,004) соответственно. Увеличение экспрессии PD-L1 клона SP142, определенное методом CPS, уменьшает шансы летального исхода в 1,54 раза (p=0,005). ЗАКЛЮЧЕНИЕ Выживаемость пациентов в группе PD-L1-позитивных опухолей значимо выше, чем в группе PD-L1-негативных новообразований. Увеличение уровня экспрессии PD-L1 клонов SP263 и SP142 является прогностическим признаком, уменьшающим шансы летального исхода у пациентов, несмотря на отсутствие адъювантной терапии ингибиторами контрольных точек иммунитета у данных больных.


  • Mucins expression in gastric cancer: connection of MUC status with clinical, morphological and prognostic characteristics of the tumor

    by N.V. Danilova, A.V. Chayka, V.M. Khomyakov, N.A. Oleynikova, Yu.YU. Andreeva, P.G. Malkov, T.N. Sotnikova

    ЦЕЛЬ ИССЛЕДОВАНИЯ Уточнение прогностической ценности и связи MUC-фенотипов рака желудка с клинико-морфологическими параметрами. МАТЕРИАЛ И МЕТОДЫ Использован операционный материал от 310 пациентов с верифицированным диагнозом рака желудка. Образцы окрашены иммуногистохимическим методом антителами к MUC2, CD10, MUC5AC. Результаты сопоставлены с клинико-морфологическими характеристиками рака желудка и данными по выживаемости пациентов. РЕЗУЛЬТАТЫ Группы MUC-null и MUC-mix по преобладанию субтотальных/тотальных опухолей значимо отличаются от группы MUC-I (p=0,022 и p=0,007 соответственно), где таких опухолей значимо меньше. В группе MUC-null чаще встречаются тубулярные опухоли по сравнению с группами MUC-G (p=0,026) и MUC-mix (p=0,006), а также в группе MUC-null меньше случаев с наличием перстневидных клеток (p=0,000). При изучении дискогезивного гистологического типа для статуса MUC-G не подтверждены данные литературы о меньших размерах опухолей и более низкой частоте лимфогенного метастазирования, но выявлена более частая проксимальная локализация опухолей MUC-I (p=0,003). Статистически значимых различий в выживаемости при анализе общей выборки не обнаружено. Различия в выживаемости обнаружены только в дискогезивных раках, где лучшая выживаемость зафиксирована для группы MUC-null, а худшая — для MUC-mix (p=0,022). MUC-статус не является независимым прогностическим признаком при раке желудка (HR=1,662, p=0,093). ЗАКЛЮЧЕНИЕ Между опухолями с разными MUC-статусами отмечены различия в локализации и принадлежности к отдельным гистологическим типам. Значимые различия по выживаемости обнаружены только для дискогезивных раков со статусами MUC-null и MUC-mix. Разделение раков желудка в зависимости от MUC-статуса может иметь лишь ограниченную прогностическую ценность в отдельных гистологических формах рака.